Drug Trial Radar · NCT00724789
Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)
Last checked: Nov 20, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,066
Actual
Start
Nov 2000
Primary completion
Nov 2005
Study completion Nov 2005
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jul 30, 2008
Design
- Study type
- Observational
- Who can join
- Female only, from 18 years, up to 39 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.
Conditions
- Pregnancy
- Neonates
Interventions
ganirelixDrug
Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
GnRH agonistDrug
Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
Primary outcomes
What the sponsor says the trial is designed to measure.
- To collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian hyperstimulation.Time frame: In both cohorts a follow-up pediatric evaluation was scheduled within 6 months post-partum
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.